JP2025509304A5 - - Google Patents
Info
- Publication number
- JP2025509304A5 JP2025509304A5 JP2024553456A JP2024553456A JP2025509304A5 JP 2025509304 A5 JP2025509304 A5 JP 2025509304A5 JP 2024553456 A JP2024553456 A JP 2024553456A JP 2024553456 A JP2024553456 A JP 2024553456A JP 2025509304 A5 JP2025509304 A5 JP 2025509304A5
- Authority
- JP
- Japan
- Prior art keywords
- adrenomedullin
- antibody
- adm
- pharmaceutical
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22162271 | 2022-03-15 | ||
| EP22162271.5 | 2022-03-15 | ||
| PCT/EP2023/056663 WO2023175035A1 (en) | 2022-03-15 | 2023-03-15 | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509304A JP2025509304A (ja) | 2025-04-11 |
| JP2025509304A5 true JP2025509304A5 (enExample) | 2026-03-13 |
Family
ID=80780591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553456A Pending JP2025509304A (ja) | 2022-03-15 | 2023-03-15 | 抗アドレノメデュリン（ａｄｍ）抗体又は抗ａｄｍ抗体フラグメントの安定な水性製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250304671A1 (enExample) |
| EP (1) | EP4493588A1 (enExample) |
| JP (1) | JP2025509304A (enExample) |
| CN (1) | CN119072492A (enExample) |
| AU (1) | AU2023233838A1 (enExample) |
| CA (1) | CA3254142A1 (enExample) |
| IL (1) | IL315632A (enExample) |
| MX (1) | MX2024010899A (enExample) |
| WO (1) | WO2023175035A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025056807A1 (en) * | 2023-09-15 | 2025-03-20 | Basf Se | Stabilized biopolymer composition, their manufacture and use |
| WO2025133235A1 (en) * | 2023-12-22 | 2025-06-26 | Pam Theragnostics Gmbh | Adm-gly as marker for early predicting sepsis |
| WO2026046978A1 (en) * | 2024-08-26 | 2026-03-05 | Pam Theragnostics Gmbh | Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| AU2002213441B2 (en) * | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| AU2002323501C1 (en) | 2001-08-30 | 2010-04-29 | Biorexis Technology, Inc | Modified transferrin fusion proteins |
| EP1620734A1 (en) | 2003-04-25 | 2006-02-01 | Genova Ltd. | Secreted polypeptide species reduced cardiovascular disorders |
| US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| US20070280886A1 (en) | 2004-09-09 | 2007-12-06 | Bayer Healthcare Ag | Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr) |
| AU2005287557B2 (en) | 2004-09-21 | 2011-10-13 | Biontech Ag | Use of microproteins as tryptase inhibitors |
| ES2373832T3 (es) | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| BRPI0921469B1 (pt) | 2008-11-03 | 2022-01-18 | Molecular Partners Ag | Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica |
| MX2012002428A (es) | 2009-08-27 | 2012-09-12 | Covagen Ag | Compuestos de union il-17 y usos medicos de los mismos. |
| RU2553333C2 (ru) | 2009-12-14 | 2015-06-10 | Сцил Протеинс Гмбх | Способ идентификации гетеромультимерных модифицированных убиквитиновых белков со способностью связываться с лигандами |
| PL2580236T3 (pl) | 2010-06-08 | 2019-09-30 | Pieris Pharmaceuticals Gmbh | Muteiny lipokaliny łez wiążące IL-4 R alfa |
| ES2494190T3 (es) | 2011-11-16 | 2014-09-15 | Adrenomed Ag | Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo |
| IL283215B2 (en) | 2011-11-16 | 2024-05-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment and pharmaceutical compostions comprising the same |
| LT3553084T (lt) | 2011-11-16 | 2023-03-10 | Adrenomed Ag | Anti-adrenomedulino (adm) antikūnas arba anti-adm antikūno fragmentas, arba anti-adm ne-ig karkasas, skirtas organų funkcijos sutrikimo arba organų nepakankamumo profilaktikai arba sumažinimui paciento, sergančio lėtine arba ūmine liga arba esančio ūminės būklės, organizme |
| EP2780370B1 (en) | 2011-11-16 | 2019-09-25 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
| PT2780371T (pt) | 2011-11-16 | 2019-01-30 | Adrenomed Ag | Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm para a regulação do equilíbrio de fluidos num doente com uma doença aguda ou crónica |
| DE112017002105T5 (de) | 2016-04-21 | 2019-04-25 | Sphingotec Therapeutics Gmbh | Verfahren zur Bestimmung von DPP3 und therapeutische Verfahren |
| JP7727371B2 (ja) | 2016-12-16 | 2025-08-21 | アドレノメト アクチェンゲゼルシャフト | うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 |
| WO2019077082A1 (en) * | 2017-10-18 | 2019-04-25 | Adrenomed Ag | SURVEILLANCE OF THERAPY UNDER TREATMENT WITH ANTI-ADRENOMEDULIN BINDER (ADM) |
| CN115244080A (zh) * | 2020-02-27 | 2022-10-25 | 艾德里诺医药公司 | 用于治疗或预防休克的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架 |
-
2023
- 2023-03-15 CA CA3254142A patent/CA3254142A1/en active Pending
- 2023-03-15 CN CN202380036069.7A patent/CN119072492A/zh active Pending
- 2023-03-15 AU AU2023233838A patent/AU2023233838A1/en active Pending
- 2023-03-15 EP EP23711082.0A patent/EP4493588A1/en active Pending
- 2023-03-15 IL IL315632A patent/IL315632A/en unknown
- 2023-03-15 JP JP2024553456A patent/JP2025509304A/ja active Pending
- 2023-03-15 US US18/844,746 patent/US20250304671A1/en active Pending
- 2023-03-15 WO PCT/EP2023/056663 patent/WO2023175035A1/en not_active Ceased
-
2024
- 2024-09-05 MX MX2024010899A patent/MX2024010899A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025509304A5 (enExample) | ||
| JP6224608B2 (ja) | 血液循環を安定化させるための、患者の急性疾患又は急性病態の治療法における使用に向けた、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| JP6321545B2 (ja) | 治療法における使用のための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| CN111511390B (zh) | 用于治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂 | |
| JP6321544B2 (ja) | 慢性若しくは急性疾患又は急性病態に罹患している患者の死亡リスクを低減するための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| JP6193871B2 (ja) | 慢性若しくは急性疾患又は急性病態に罹患している患者の臓器機能障害又は臓器不全を予防又は軽減するための、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| US20160159900A1 (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease | |
| JP2020535151A5 (enExample) | ||
| JP2023052614A (ja) | うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場 | |
| JP2025509304A (ja) | 抗アドレノメデュリン（ａｄｍ）抗体又は抗ａｄｍ抗体フラグメントの安定な水性製剤 | |
| RU2854796C1 (ru) | Связующее вещество против адреномедуллина (adm) для применения в терапии пациентов в состоянии шока | |
| RU2790561C2 (ru) | Соединение, связывающее адреномедуллин (adm), для применения для терапии или профилактики симптомов заболевания | |
| HK40120923A (zh) | 用於治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂 | |
| HK40120349A (en) | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness | |
| HK40058594A (en) | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness | |
| HK40085254A (en) | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness | |
| HK40083955A (en) | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness | |
| US20230250166A1 (en) | Anti-adrenomedullin (adm) binder for use in therapy of patients in shock | |
| HK40032645B (zh) | 用於治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂 | |
| JP2023553571A (ja) | 急性及び／又は持続性呼吸困難を有する患者に対する併用療法 | |
| RU2022112502A (ru) | Соединение, связывающее адреномедуллин (adm), для применения для терапии или профилактики симптомов заболевания | |
| HK40032645A (en) | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness | |
| HK1225640B (zh) | 治疗脂肪组织积聚的组合物和方法 |